Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 10, 2015; 6(4): 45-56
Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.45
Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.45
Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?
Edurne Arriola, Álvaro Taus, David Casadevall, Oncology Department, Hospital del Mar, 08003 Barcelona, Spain
Author contributions: The research was designed by Arriola E; Taus A and Casadevall D conducted this work; Arriola E, Taus A and Casadevall D analysed the data; Arriola E, Taus A and Casadevall D wrote the paper.
Conflict-of-interest statement: The authors disclose no potential conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Edurne Arriola, Oncology Department, Hospital del Mar, Passeig Marítim de la Barceloneta, 25-29, 08003 Barcelona, Spain. earriola@parcdesalutmar.cat
Telephone: +34-932-483000 Fax: +34-932-483366
Received: February 20, 2015
Peer-review started: February 22, 2015
First decision: April 20, 2015
Revised: May 8, 2015
Accepted: June 4, 2015
Article in press: June 8, 2015
Published online: August 10, 2015
Peer-review started: February 22, 2015
First decision: April 20, 2015
Revised: May 8, 2015
Accepted: June 4, 2015
Article in press: June 8, 2015
Published online: August 10, 2015
Core Tip
Core tip: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are well established as the treatment of choice in EGFR-mutant non-small cell lung cancer. However, they are approved and have shown efficacy in patients with wild-type disease. Here, we review the clinical data showing this consistent benefit in a subgroup of patients and the potential biological mechanisms of this clinical effect.